# Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

> **NCT04999969** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 126 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumours

## Interventions

- **DRUG:** AZD0171
- **DRUG:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT04999969
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-10
- **Primary completion:** 2024-10-07
- **Final completion:** 2026-06-30
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04999969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04999969, "Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04999969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*